Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIFC1 | Q9BW19 | 2/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 5/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.35 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311174 | 0.91 | ADRB2 (0.43) | ADRB2ITGB1ITGA4ITGB7PPARG | |
| SCHEMBL4479161 | 0.83 | ITGB3 (0.43) | KIFC1FPR2ACEITGB1ITGA4 | |
| SCHEMBL4479163 | 0.83 | ITGB3 (0.43) | KIFC1FPR2ACEITGB1ITGA4 | |
| SCHEMBL3316808 | 0.83 | ITGB3 (0.48) | KIFC1ACEECE1 | |
| SCHEMBL4456532 | 0.76 | GRB2 (0.50) | — | |
| SCHEMBL4456537 | 0.76 | GRB2 (0.50) | — | |
| SCHEMBL29855462 | 0.75 | FPR2 (0.58) | KIFC1FPR2ACEITGB1ITGA4 | |
| SCHEMBL3316803 | 0.74 | TACR1 (0.44) | EPHX2PPARG | |
| SCHEMBL3310634 | 0.74 | TACR1 (0.44) | EPHX2PPARG | |
| SCHEMBL1093170 | 0.73 | CA2 (0.50) | ACEITGB1MMECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | KIFC1 4514/4885FPR2 432/4885ACE 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.